MPS VI

Inventiva draws down €25 million tranche under Finance Contract with the European Investment Bank

Retrieved on: 
Monday, December 12, 2022

Jean Volatier, Chief Financial Officer of Inventiva, stated: “We are pleased to see that our long-term partnership with the EIB is bearing fruit.

Key Points: 
  • Jean Volatier, Chief Financial Officer of Inventiva, stated: “We are pleased to see that our long-term partnership with the EIB is bearing fruit.
  • Any drawings under the terms of the Finance Contract that have not been disbursed within 36 months from the signing of the Finance Contract, (i.e., before May 16, 2025), cannot be completed at a later date.
  • On November 4, 2022, the Company received an upfront payment of $12 million under its collaboration agreement with Sino Biopharm.
  • on December 8, 2026), (ii) a change of control event, (iii) an event of default under the Finance Contract, or (iv) a repayment demand by EIB under the Finance Contract.

Inventiva reports its 2022 first-half financial results and provides a corporate update

Retrieved on: 
Thursday, September 22, 2022

Other operating income (expenses) amounted to 0.1 million in the first half of 2022 compared to (0.6) million in the first half of 2021.

Key Points: 
  • Other operating income (expenses) amounted to 0.1 million in the first half of 2022 compared to (0.6) million in the first half of 2021.
  • The Companys net loss stood at (29.5) million in the first half of 2022 compared to (23.1) million in the first half of 2021.
  • Net cash used in operating activities amounted to 26.2 million in the first half of 2022 compared to 19.8 million for the same period in 2021.
  • The financial statements of the first half of 2022 were approved by Inventivas Board of Directors on September 21, 2022.

Inventiva announces participation at several conferences in March 2022

Retrieved on: 
Tuesday, March 1, 2022

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical need.

Key Points: 
  • Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical need.
  • Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing lanifibranor, as well as other earlier stage programs.
  • Inventivas pipeline also includes odiparcil, a drug candidate for the treatment of patients with subtypes of MPS, a group of rare genetic disorders.
  • In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.

Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results

Retrieved on: 
Monday, February 28, 2022

Inventivas 2021 full-year financial results will be released on Monday, March 7, 2022 at 4:00 pm (New York), 10:00 pm (Paris).

Key Points: 
  • Inventivas 2021 full-year financial results will be released on Monday, March 7, 2022 at 4:00 pm (New York), 10:00 pm (Paris).
  • The conference call and the slides of the presentation will be webcast live at: https://edge.media-server.com/mmc/p/wo3raaz4 and also available on Inventivas onwards in the Investors Financial results section.
  • A replay of the conference call and the presentation will be available after the event at: http://inventivapharma.com/investors/financial-results-presentations/ .
  • In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.

Inventiva reports cash position and revenues for Full-Year 2021

Retrieved on: 
Monday, February 14, 2022

As of December 31, 2021, Inventivas cash position2 stood at 95.4 million, including 86.6 million of cash and cash equivalents and 8.8 million of short-term deposits, compared to 105.7 million as of September 30, 2021 (comprising only cash and cash equivalent), and 113.0 million as of December 31, 2020, including

Key Points: 
  • As of December 31, 2021, Inventivas cash position2 stood at 95.4 million, including 86.6 million of cash and cash equivalents and 8.8 million of short-term deposits, compared to 105.7 million as of September 30, 2021 (comprising only cash and cash equivalent), and 113.0 million as of December 31, 2020, including
    105.7 million of cash and cash equivalents and 7.3 million of short-term deposits, respectively.
  • Net cash used in operating activities amounted to (47.7) million for the full year 2021, compared
    to (30.6) million in 2020.
  • The sales were made through the Company's At-The-Market program established on August 2, 2021, to existing and new specialized institutional investors.
  • In 2021, the Company recorded a positive exchange rate effect on cash and cash equivalents of 5.0 million.

Proactive news headlines including Chimeric Therapeutics, Radiopharm Theranostics, Magnis Energy Technologies and Euro Manganese

Retrieved on: 
Friday, February 11, 2022

Click here

Key Points: 
  • Click here
    Magnis Energy Technologies Ltd (ASX:MNS, OTCQX:MNSEF) continues to advance its wholly-owned Nachu Graphite Project in Tanzania towards production.
  • Click here
    Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has entered the final stage of development for a new hemp-based lozenge, potentially expanding its international opportunities.
  • Click here
    First Graphene Ltd (ASX:FGR, OTCQB:FGPHF) is set to introduce its battery anode solution to the UK market.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006
    For more information on how Proactive can help you make a difference, email us at [email protected]

Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation

Retrieved on: 
Monday, January 31, 2022

It follows the inclusion of the first patient with psoriasis in the ongoing Phase IIb clinical trial with cedirogant (ABBV-157)1, an oral RORg inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases.

Key Points: 
  • It follows the inclusion of the first patient with psoriasis in the ongoing Phase IIb clinical trial with cedirogant (ABBV-157)1, an oral RORg inverse agonist jointly discovered by Inventiva and AbbVie for the treatment of autoimmune diseases.
  • Frdric Cren, Chairman, Chief Executive Officer and cofounder of Inventiva, stated: This new milestone payment and the initiation of a Phase IIb trial in adult patients with psoriasis are excellent news for Inventiva.
  • It is an important step in the development of cedirogant, after the compound showed promising activity as an oral psoriasis agent in a Phase Ib clinical trial led by AbbVie.
  • In 2012, Inventiva and AbbVie signed a multi-year drug discovery collaboration agreement to identify potent RORg inverse agonists for the treatment of several auto-immune diseases.

Inventiva announces participation at several conferences in January and February 2022

Retrieved on: 
Thursday, January 20, 2022

The event details are as follows:

Key Points: 
  • The event details are as follows:
    The links to these events will also be available on Inventivas website in the Investors Investor Presentations section.
  • Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.
  • In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.
  • AbbVie has started the clinical development of cedirogant (ABBV157), a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva.

Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, December 16, 2021

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.

Key Points: 
  • Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.
  • Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of preclinical programs.
  • Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders.
  • In parallel, Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.

Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor

Retrieved on: 
Monday, December 6, 2021

The clinical trial enrolled 217 healthy subjects who were randomized into four arms, placebo, lanifibranor 1200mg/day (anticipated maximal therapeutic dose), lanifibranor 2400mg/day (supra-therapeutic dose), and moxifloxacin 400mg/day (positive control).

Key Points: 
  • The clinical trial enrolled 217 healthy subjects who were randomized into four arms, placebo, lanifibranor 1200mg/day (anticipated maximal therapeutic dose), lanifibranor 2400mg/day (supra-therapeutic dose), and moxifloxacin 400mg/day (positive control).
  • Michael Cooreman, Chief Medical Officer , stated: Thorough QT studies are conducted to measure the potential risk for a drug to lead to arrhythmia.
  • This study confirms the safety of lanifibranor on cardiac activity previously observed in our Phase II studies.
  • In 2020, Inventiva announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained both FDA Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.